NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT06465433 2025-12-10
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Incyte Corporation
Phase 2 Recruiting
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT01685021 2018-02-22
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
MorphoSys AG
Phase 2 Terminated
NCT01161511 2014-04-21
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Xencor, Inc.
Phase 1 Completed